Vor Biopharma Inc.
VOR
$16.10
$1.177.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 93.30% | 44.12% | 0.78% | -28.21% | -15.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 181.46% | 182.16% | 185.84% | 169.76% | -4.53% |
| Operating Income | -181.46% | -182.16% | -185.84% | -169.76% | 4.53% |
| Income Before Tax | -644.61% | -495.29% | -2,078.10% | -1,309.41% | 1.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -644.61% | -495.29% | -2,078.10% | -1,309.41% | 1.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -644.61% | -495.29% | -2,078.10% | -1,309.41% | 1.36% |
| EBIT | -181.46% | -182.16% | -185.84% | -169.76% | 4.53% |
| EBITDA | -187.79% | -188.17% | -191.46% | -173.99% | 4.51% |
| EPS Basic | -871.17% | -761.56% | -1,072.25% | -685.97% | 15.13% |
| Normalized Basic EPS | -856.10% | -748.20% | -1,057.86% | -671.86% | 15.13% |
| EPS Diluted | -871.17% | -761.56% | -1,072.25% | -685.97% | 15.13% |
| Normalized Diluted EPS | -856.10% | -748.20% | -1,057.86% | -671.86% | 15.13% |
| Average Basic Shares Outstanding | 359.88% | 187.33% | 66.43% | 42.98% | 22.59% |
| Average Diluted Shares Outstanding | 359.88% | 187.33% | 66.43% | 42.98% | 22.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |